Jazz Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Jazz Pharmaceuticals's earnings have been declining at an average annual rate of -10.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 14.4% per year. Jazz Pharmaceuticals's return on equity is 11.1%, and it has net margins of 11.6%.
Key information
-10.3%
Earnings growth rate
-13.3%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 14.4% |
Return on equity | 11.1% |
Net Margin | 11.6% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve
Nov 14Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Oct 22Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Revenue & Expenses Breakdown
How Jazz Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 3,993 | 463 | 1,376 | 834 |
30 Jun 24 | 3,910 | 395 | 1,359 | 869 |
31 Mar 24 | 3,843 | 331 | 1,361 | 857 |
31 Dec 23 | 3,834 | 415 | 1,307 | 824 |
30 Sep 23 | 3,794 | 80 | 1,269 | 782 |
30 Jun 23 | 3,763 | -87 | 1,378 | 685 |
31 Mar 23 | 3,738 | -156 | 1,397 | 615 |
31 Dec 22 | 3,659 | -224 | 1,399 | 555 |
30 Sep 22 | 3,584 | -19 | 1,276 | 532 |
30 Jun 22 | 3,481 | -52 | 1,222 | 536 |
31 Mar 22 | 3,300 | -450 | 1,291 | 530 |
31 Dec 21 | 3,094 | -330 | 1,399 | 476 |
30 Sep 21 | 2,863 | -161 | 1,326 | 416 |
30 Jun 21 | 2,626 | 40 | 1,170 | 354 |
31 Mar 21 | 2,436 | 518 | 926 | 306 |
31 Dec 20 | 2,364 | 239 | 880 | 310 |
30 Sep 20 | 2,280 | 179 | 846 | 316 |
30 Jun 20 | 2,217 | 133 | 818 | 317 |
31 Mar 20 | 2,188 | 280 | 808 | 295 |
31 Dec 19 | 2,162 | 523 | 762 | 275 |
30 Sep 19 | 2,056 | 609 | 626 | 259 |
30 Jun 19 | 1,988 | 656 | 662 | 230 |
31 Mar 19 | 1,954 | 486 | 586 | 224 |
31 Dec 18 | 1,891 | 447 | 625 | 227 |
30 Sep 18 | 1,851 | 520 | 667 | 234 |
30 Jun 18 | 1,793 | 434 | 578 | 230 |
31 Mar 18 | 1,687 | 447 | 610 | 214 |
31 Dec 17 | 1,619 | 488 | 544 | 198 |
30 Sep 17 | 1,579 | 372 | 518 | 175 |
30 Jun 17 | 1,541 | 399 | 505 | 175 |
31 Mar 17 | 1,528 | 408 | 496 | 174 |
31 Dec 16 | 1,488 | 397 | 480 | 160 |
30 Sep 16 | 1,432 | 363 | 470 | 148 |
30 Jun 16 | 1,399 | 361 | 462 | 151 |
31 Mar 16 | 1,352 | 335 | 447 | 139 |
31 Dec 15 | 1,325 | 330 | 433 | 133 |
30 Sep 15 | 1,312 | 328 | 422 | 130 |
30 Jun 15 | 1,278 | 266 | 411 | 102 |
31 Mar 15 | 1,235 | 222 | 399 | 94 |
31 Dec 14 | 1,173 | 58 | 404 | 85 |
30 Sep 14 | 1,081 | 32 | 350 | 74 |
30 Jun 14 | 1,006 | 82 | 327 | 64 |
31 Mar 14 | 923 | 80 | 305 | 53 |
31 Dec 13 | 872 | 216 | 281 | 42 |
Quality Earnings: JAZZ has a large one-off loss of $219.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: JAZZ's current net profit margins (11.6%) are higher than last year (2.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JAZZ's earnings have declined by 10.3% per year over the past 5 years.
Accelerating Growth: JAZZ's earnings growth over the past year (479.3%) exceeds its 5-year average (-10.3% per year).
Earnings vs Industry: JAZZ earnings growth over the past year (479.3%) exceeded the Pharmaceuticals industry 54.6%.
Return on Equity
High ROE: JAZZ's Return on Equity (11.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 02:34 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joel Beatty | Baird |
Ishan Majumdar | Baptista Research |
Richard Silver | Barclays |